SCHEMBL350156

SCHEMBL350156

COC1=CC[CH]C=C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10904062 0.78
SCHEMBL4587168 0.75
SCHEMBL5616769 0.75
SCHEMBL5252355 0.74
SCHEMBL7068841 0.74
SCHEMBL7276585 0.71
SCHEMBL7603559 0.70 TSHR (0.33)
SCHEMBL11661421 0.70 ALDH1A1 (0.30)
SCHEMBL5604442 0.70
SCHEMBL4365238 0.68

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 252 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11932658-B2 Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as PAR4 inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2024-03-19 US claimed
CN-113195483-A Novel oxadiazole compound PI工业有限公司 2021-07-30 CN claimed
EP-3484894-B1 TRICYCLIC HETEROARYL-SUBSTITUTED QUINOLINE AND AZAQUINOLINE COMPOUNDS AS PAR4 INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2020-08-19 EP claimed
EP-3484894-A1 TRICYCLIC HETEROARYL-SUBSTITUTED QUINOLINE AND AZAQUINOLINE COMPOUNDS AS PAR4 INHIBITORS Bristol-Myers Squibb Company (US) 2019-05-22 EP claimed
WO-2018013776-A1 TRICYCLIC HETEROARYL-SUBSTITUTED QUINOLINE AND AZAQUINOLINE COMPOUNDS AS PAR4 INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2018-01-18 WO claimed
WO-2017196762-A1 SILICONE COMPOUNDS THE PROCTER & GAMBLE COMPANY (US) 2017-11-16 WO claimed
US-9770446-B2 Piperidine urea derivatives MERCK PATENT GMBH (DE) 2017-09-26 US claimed
EP-3218425-A1 SILICONE COMPOUNDS The Procter and Gamble Company (US) 2017-09-20 EP claimed
EP-3129102-A1 IODONIUM ANALOGS AS INHIBITORS OF NADPH OXIDASES AND OTHER FLAVIN DEHYDROGENASES; FORMULATIONS THEREOF; AND USES THEREOF The U.S.A. As Represented By The Secretary, Department Of Health And Human Services (US) 2017-02-15 EP claimed
US-20160184285-A1 PIPERIDINE UREA DERIVATIVES MERCK PATENT GMBH (DE) 2016-06-30 US claimed
EP-1874769-B1 NOVEL AZA- HETEROCYCLES SERVING AS KINASE INHIBITORS MERCK PATENT GMBH (DE) 2011-09-14 EP claimed
EP-2170864-B1 PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS BRISTOL MYERS SQUIBB CO (US) 2011-09-14 EP claimed
EP-1509489-B1 AMINES THAT INHIBIT A MAMMALIAN ANANDAMIDE TRANSPORTER, AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC (US) 2011-07-13 EP claimed
EP-2323612-A1 SERIES OF SKIN-WHITENING (LIGHTENING) COMPOUNDS Unigen, Inc. (US) 2011-05-25 EP claimed
WO-2010011630-A1 SERIES OF SKIN-WHITENING (LIGHTENING) COMPOUNDS UNIGEN PHARMACEUTICALS, INC. (US) 2010-01-28 WO claimed
WO-2007077479-A1 SPIRO-1,2,4-TRIOXANES AS ANTIMALARIAL AGENTS COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2007-07-12 WO claimed
WO-2006070381-A1 AMINO-FUNCTIONALIZED 1,2,4-TRIOXANES USEFUL AS ANTI-MALARIAL AGENTS AND PROCESS FOR PREPARATION THEREOF COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2006-07-06 WO claimed
CN-1422262-A 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors ABBOTT GMBH & CO KG (DE) 2003-06-04 CN claimed
EP-0590489-B1 New cyclopentanperhydrophenanthren-17beta-(hydroxy or alkoxy)-17alpha-(aryl or heterocyclyl)-3beta-derivatives active on the cardiovascular system, processes for their preparation and pharmaceutical compositions containing same SIGMA TAU IND FARMACEUTI (IT) 1996-12-11 EP claimed
EP-0590489-A2 New cyclopentanperhydrophenanthren-17beta-(hydroxy or alkoxy)-17alpha-(aryl or heterocyclyl)-3beta-derivatives active on the cardiovascular system, processes for their preparation and pharmaceutical compositions containing same Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) 1994-04-06 EP claimed